|
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
RECRUITINGSponsored by Hunan Cancer Hospital
Actively Recruiting
SponsorHunan Cancer Hospital
Started2019-03-01
Est. completion2028-03-01
Eligibility
Age18 Years – 75 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05326295
Summary
The phenotype of circulating tumor cells (CTCs) is supposed to be significant indicator that is correlated the prognosis of breast cancer patients who have completed neoadjuvant chemotherapy, primary tumor surgery with/without adjuvant chemotherapy. The aim of this observational study is to assess the efficacy of CTCs surveillance in predicting the prognosis of breast cancer patients.
Eligibility
Age: 18 Years – 75 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria * The age is more than 18 years old; * Pathology confirmed malignant breast tumor; * No clinical diagnosis of other malignancies, unstable complications or uncontrolled infection; * Life expectancy is greater than 6 month; * The main organ function is normal; * The subjects volunteered to participate in this study, signed informed consent, followed up with good compliance. Exclusion Criteria * Patients who had suffered from other malignant tumors; * With uncontrolled bacterial, viral or fungal infections; * With physical or mental disorders * Without or limited civil capacity; * Infected with human immunodeficiency virus (HIV); * Circumstances in which the investigator considers it inappropriate to participate in this study.
Conditions5
Breast CancerBreast NeoplasmsCancerChemotherapy EffectNeoplastic Cells, Circulating
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorHunan Cancer Hospital
Started2019-03-01
Est. completion2028-03-01
Eligibility
Age18 Years – 75 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05326295